193 related articles for article (PubMed ID: 35050342)
1. Evaluation of Substantial Reduction in Elective Radiotherapy Dose and Field in Patients With Human Papillomavirus-Associated Oropharyngeal Carcinoma Treated With Definitive Chemoradiotherapy.
Tsai CJ; McBride SM; Riaz N; Kang JJ; Spielsinger DJ; Waldenberg T; Gelblum D; Yu Y; Chen LC; Zakeri K; Wong RJ; Dunn L; Pfister DG; Sherman EJ; Lee NY
JAMA Oncol; 2022 Mar; 8(3):364-372. PubMed ID: 35050342
[TBL] [Abstract][Full Text] [Related]
2. Phase II Trial of De-Intensified Chemoradiotherapy for Human Papillomavirus-Associated Oropharyngeal Squamous Cell Carcinoma.
Chera BS; Amdur RJ; Green R; Shen C; Gupta G; Tan X; Knowles M; Fried D; Hayes N; Weiss J; Grilley-Olson J; Patel S; Zanation A; Hackman T; Zevallos J; Blumberg J; Patel S; Kasibhatla M; Sheets N; Weissler M; Yarbrough W; Mendenhall W
J Clin Oncol; 2019 Oct; 37(29):2661-2669. PubMed ID: 31411949
[TBL] [Abstract][Full Text] [Related]
3. Phase II Evaluation of Aggressive Dose De-Escalation for Adjuvant Chemoradiotherapy in Human Papillomavirus-Associated Oropharynx Squamous Cell Carcinoma.
Ma DJ; Price KA; Moore EJ; Patel SH; Hinni ML; Garcia JJ; Graner DE; Foster NR; Ginos B; Neben-Wittich M; Garces YI; Chintakuntlawar AV; Price DL; Olsen KD; Van Abel KM; Kasperbauer JL; Janus JR; Waddle M; Miller R; Shiraishi S; Foote RL
J Clin Oncol; 2019 Aug; 37(22):1909-1918. PubMed ID: 31163012
[TBL] [Abstract][Full Text] [Related]
4. Mature results of a prospective study of deintensified chemoradiotherapy for low-risk human papillomavirus-associated oropharyngeal squamous cell carcinoma.
Chera BS; Amdur RJ; Tepper JE; Tan X; Weiss J; Grilley-Olson JE; Hayes DN; Zanation A; Hackman TG; Patel S; Sheets N; Weissler MC; Mendenhall WM
Cancer; 2018 Jun; 124(11):2347-2354. PubMed ID: 29579339
[TBL] [Abstract][Full Text] [Related]
5. De-Escalated Adjuvant Therapy After Transoral Robotic Surgery for Human Papillomavirus-Related Oropharyngeal Carcinoma: The Sinai Robotic Surgery (SIRS) Trial.
Miles BA; Posner MR; Gupta V; Teng MS; Bakst RL; Yao M; Misiukiewicz KJ; Chai RL; Sharma S; Westra WH; Kim-Schulze S; Dayal B; Sobotka S; Sikora AG; Som PM; Genden EM
Oncologist; 2021 Jun; 26(6):504-513. PubMed ID: 33675133
[TBL] [Abstract][Full Text] [Related]
6. Quality of Life and Depression Symptoms After Therapy De-Escalation in HPV+ Oropharyngeal Squamous Cell Carcinoma: A Nonrandomized Controlled Trial.
Panwar A; Shah S; Reid AE; Lydiatt W; Holcomb AJ; Osmolak A; Coughlin A; Militsakh O; Su YB; Mirmiran A; Huang TS; Nolan N; Duckert R; Barney C; Chiu M; Nguyen C; Sayles H; Ganti AK; Lindau R
JAMA Otolaryngol Head Neck Surg; 2024 May; 150(5):429-435. PubMed ID: 38573597
[TBL] [Abstract][Full Text] [Related]
7. Radiographic retropharyngeal lymph node involvement in HPV-associated oropharyngeal carcinoma: Patterns of involvement and impact on patient outcomes.
Lin TA; Garden AS; Elhalawani H; Elgohari B; Jethanandani A; Ng SP; Mohamed AS; Frank SJ; Glisson BS; Debnam JM; Sturgis EM; Phan J; Reddy JP; Fuller CD; Morrison WH; Skinner HD; Rosenthal DI; Gunn GB
Cancer; 2019 May; 125(9):1536-1546. PubMed ID: 30620385
[TBL] [Abstract][Full Text] [Related]
8. Reduced-dose radiotherapy for human papillomavirus-associated squamous-cell carcinoma of the oropharynx: a single-arm, phase 2 study.
Chen AM; Felix C; Wang PC; Hsu S; Basehart V; Garst J; Beron P; Wong D; Rosove MH; Rao S; Melanson H; Kim E; Palmer D; Qi L; Kelly K; Steinberg ML; Kupelian PA; Daly ME
Lancet Oncol; 2017 Jun; 18(6):803-811. PubMed ID: 28434660
[TBL] [Abstract][Full Text] [Related]
9. Prospective study evaluating dynamic changes of cell-free HPV DNA in locoregional viral-associated oropharyngeal cancer treated with induction chemotherapy and response-adaptive treatment.
Rosenberg AJ; Izumchenko E; Pearson A; Gooi Z; Blair E; Karrison T; Juloori A; Ginat D; Cipriani N; Lingen M; Sloane H; Edelstein DL; Keyser K; Fredebohm J; Holtrup F; Jones FS; Haraf D; Agrawal N; Vokes EE
BMC Cancer; 2022 Jan; 22(1):17. PubMed ID: 34980038
[TBL] [Abstract][Full Text] [Related]
10. Radiotherapy plus cetuximab or cisplatin in human papillomavirus-positive oropharyngeal cancer (NRG Oncology RTOG 1016): a randomised, multicentre, non-inferiority trial.
Gillison ML; Trotti AM; Harris J; Eisbruch A; Harari PM; Adelstein DJ; Jordan RCK; Zhao W; Sturgis EM; Burtness B; Ridge JA; Ringash J; Galvin J; Yao M; Koyfman SA; Blakaj DM; Razaq MA; Colevas AD; Beitler JJ; Jones CU; Dunlap NE; Seaward SA; Spencer S; Galloway TJ; Phan J; Dignam JJ; Le QT
Lancet; 2019 Jan; 393(10166):40-50. PubMed ID: 30449625
[TBL] [Abstract][Full Text] [Related]
11. OPTIMA: a phase II dose and volume de-escalation trial for human papillomavirus-positive oropharyngeal cancer.
Seiwert TY; Foster CC; Blair EA; Karrison TG; Agrawal N; Melotek JM; Portugal L; Brisson RJ; Dekker A; Kochanny S; Gooi Z; Lingen MW; Villaflor VM; Ginat DT; Haraf DJ; Vokes EE
Ann Oncol; 2019 Feb; 30(2):297-302. PubMed ID: 30481287
[TBL] [Abstract][Full Text] [Related]
12. Strategy of Using Intratreatment Hypoxia Imaging to Selectively and Safely Guide Radiation Dose De-escalation Concurrent With Chemotherapy for Locoregionally Advanced Human Papillomavirus-Related Oropharyngeal Carcinoma.
Lee N; Schoder H; Beattie B; Lanning R; Riaz N; McBride S; Katabi N; Li D; Yarusi B; Chan S; Mitrani L; Zhang Z; Pfister DG; Sherman E; Baxi S; Boyle J; Morris LG; Ganly I; Wong R; Humm J
Int J Radiat Oncol Biol Phys; 2016 Sep; 96(1):9-17. PubMed ID: 27511842
[TBL] [Abstract][Full Text] [Related]
13. The impact of Human Papilloma Virus status on the prediction of head and neck cancer chemoradiotherapy outcomes using the pre-treatment apparent diffusion coefficient.
Connor S; Anjari M; Burd C; Guha A; Lei M; Guerrero-Urbano T; Pai I; Bassett P; Goh V
Br J Radiol; 2022 Feb; 95(1130):20210333. PubMed ID: 34111977
[TBL] [Abstract][Full Text] [Related]
14. Deintensification candidate subgroups in human papillomavirus-related oropharyngeal cancer according to minimal risk of distant metastasis.
O'Sullivan B; Huang SH; Siu LL; Waldron J; Zhao H; Perez-Ordonez B; Weinreb I; Kim J; Ringash J; Bayley A; Dawson LA; Hope A; Cho J; Irish J; Gilbert R; Gullane P; Hui A; Liu FF; Chen E; Xu W
J Clin Oncol; 2013 Feb; 31(5):543-50. PubMed ID: 23295795
[TBL] [Abstract][Full Text] [Related]
15. T-category remains an important prognostic factor for oropharyngeal carcinoma in the era of human papillomavirus.
Mackenzie P; Pryor D; Burmeister E; Foote M; Panizza B; Burmeister B; Porceddu S
Clin Oncol (R Coll Radiol); 2014 Oct; 26(10):643-7. PubMed ID: 25001635
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of proposed staging systems for human papillomavirus-related oropharyngeal squamous cell carcinoma.
Malm IJ; Fan CJ; Yin LX; Li DX; Koch WM; Gourin CG; Pitman KT; Richmon JD; Westra WH; Kang H; Quon H; Eisele DW; Fakhry C
Cancer; 2017 May; 123(10):1768-1777. PubMed ID: 28055120
[TBL] [Abstract][Full Text] [Related]
17. Locoregional and distant recurrence for HPV-associated oropharyngeal cancer using AJCC 8 staging.
Contrera KJ; Smile TD; Mahomva C; Wei W; Adelstein DJ; Broughman JR; Burkey BB; Geiger JL; Joshi NP; Ku JA; Lamarre ED; Lorenz RR; Prendes BL; Scharpf J; Schwartzman LM; Woody NM; Xiong D; Koyfman SA
Oral Oncol; 2020 Dec; 111():105030. PubMed ID: 33038751
[TBL] [Abstract][Full Text] [Related]
18. Impact of cisplatin dose intensity on human papillomavirus-related and -unrelated locally advanced head and neck squamous cell carcinoma.
Spreafico A; Huang SH; Xu W; Granata R; Liu CS; Waldron JN; Chen E; Ringash J; Bayley A; Chan KK; Hope AJ; Cho J; Razak AA; Hansen A; Jang R; Perez-Ordonez B; Weinreb I; Bossi P; Orlandi E; Licitra LF; Song Y; O'Sullivan B; Siu LL; Kim J
Eur J Cancer; 2016 Nov; 67():174-182. PubMed ID: 27669504
[TBL] [Abstract][Full Text] [Related]
19. Phase II Randomized Trial of Transoral Surgery and Low-Dose Intensity Modulated Radiation Therapy in Resectable p16+ Locally Advanced Oropharynx Cancer: An ECOG-ACRIN Cancer Research Group Trial (E3311).
Ferris RL; Flamand Y; Weinstein GS; Li S; Quon H; Mehra R; Garcia JJ; Chung CH; Gillison ML; Duvvuri U; O'Malley BW; Ozer E; Thomas GR; Koch WM; Gross ND; Bell RB; Saba NF; Lango M; Méndez E; Burtness B
J Clin Oncol; 2022 Jan; 40(2):138-149. PubMed ID: 34699271
[TBL] [Abstract][Full Text] [Related]
20. Impact of cisplatin dose and smoking pack-years in human papillomavirus-positive oropharyngeal squamous cell carcinoma treated with chemoradiotherapy.
Oliva M; Huang SH; Xu W; Su J; Hansen AR; Bratman SV; Ringash J; Jang R; Cho J; Bayley A; Hope AJ; Chen E; Giuliani M; Waldron J; Weinreb I; Perez-Ordonez B; Chepeha D; Kim J; O Sullivan B; Siu LL; Spreafico A
Eur J Cancer; 2019 Sep; 118():112-120. PubMed ID: 31330486
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
